Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-08-04 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, the price range, total funds used, and compliance with relevant regulations. The document is relatively short (1229 characters) and focuses on the update of the share buyback activity rather than a full financial report or other types of filings. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2020-08-04 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, risk control measures, approvals by the board and shareholders, and financial impacts. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, and provides detailed financial data and risk analysis related to the use of idle raised funds for cash management. It is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy, voting result, or board change announcement. The document is a regulatory announcement about the company's capital management activities specifically related to the use of raised funds for purchasing financial products. This fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and use of capital raised through stock issuance. The document length and detail confirm it is not a brief report publication announcement or a simple regulatory filing. Therefore, the classification is CAP with high confidence.
2020-07-24 Chinese
关于使用部分闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using part of its idle funds to purchase wealth management products. It includes specifics about the entrusted financial products, amounts, expected yields, risk control measures, and approvals by the board and shareholders. The document is not a financial report like an annual or interim report, nor is it a regulatory filing or certification. It is a capital/financing update about the company's investment activities with its own funds in financial products. The length is over 5,000 characters and contains substantive financial data related to capital usage and investment returns. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-07-07 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, the price range, total funds used, and compliance with relevant laws and company resolutions. The document is relatively short (1296 characters) and focuses on the update of the share buyback activity rather than financial results or other report types. This matches the description of a Transaction in Own Shares (POS) filing, which reports on company share repurchase activities.
2020-07-01 Chinese
关于公开发行可转换公司债券申请获得中国证监会核准批复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval from the China Securities Regulatory Commission (CSRC) for the company's public issuance of convertible bonds. It details the approval, terms, and conditions of the convertible bond issuance but does not contain financial statements or detailed financial data. The document is short (597 characters) and serves as a formal notification of a capital raising activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-06-29 Chinese
前次募集资金使用情况的报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by Kunming Pharmaceutical Group Co., Ltd. It includes specifics about the amounts raised, the timing, the allocation of funds, changes in investment projects, and the actual use of the funds compared to commitments. It references regulatory approvals from the China Securities Regulatory Commission and includes detailed financial tables and project descriptions. The document is not a brief announcement but a comprehensive report on fundraising usage, which aligns with the category of Capital/Financing Update (CAP). It is not an Annual Report, Earnings Release, or Audit Report, nor is it a simple announcement or certification. The length and detail confirm it is a substantive report on capital usage and fundraising activities.
2020-06-05 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.